UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCLA Health Jonsson Comprehensive Cancer Center

Updated MONALEESA-3 Data Underscore Frontline Efficacy of Ribociclib/Fulvestrant in HR+ Advanced Breast Cancer

September 29, 2021

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24, 2021

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21, 2021

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer

September 09, 2021

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC

July 15, 2021

Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Moving Beyond Chemotherapy in Metastatic Pancreatic Cancer

April 22, 2021

Zev A. Wainberg, MD, discusses the role of neoadjuvant chemotherapy in resectable pancreatic cancer, emerging approaches in locally advanced disease, the promise of PARP inhibitors in the metastatic setting, and other future research directions of interest.